BifSol Technologies Ltd. is poised to deliver the future of Endovascular Aortic Repair (EVAR) through its propitiatory and revolutionary technology.

Minimally-invasive Endovascular Aortic Repair (EVAR) has steadily become the standard of care in the management of abdominal aortic aneurysms (AAA); it has now surpassed open surgical repair and is the predominant therapeutic modality in managing this disease entity. Today, despite great advances in product development, about 40% of patients do not qualify for conventional EVAR due to challenging anatomies; current treatment options for these patients are extremely limited.

BifSol is dedicated to the development of a pipeline of novel solutions for the treatment of aortic disorders.

BifSol aims to expand the use of EVAR for complex AAA and significantly improve the treatment of vascular bifurcations.

We're developing an off-the-shelf suprarenal stent-graft system, that is delivered to the suprarenal zone into the ultra-low profile catheter, which may support a wide range of patients, including women and Asian origins.

The New Generation of the Implants for the Complex Bifurcation Zones